Product Information

CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $0.6313 per EA under NDC 33342013210. Its NADAC has been published 536 times since Aug 17, 2016.

FDA first approved this application on Feb 27, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB

Candesartan Cilexetil and Hydrochlorothiazide
$0.6313per EA

Strength

32; 12.5 mg/1; mg/1

NDC

33342013210

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

11/18/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA204100

FDA Approved

2/27/2015

TE Code

AB

On Market Since

3/7/2015

Pharmacological Classes

Angiotensin 2 Receptor Antagonists
Angiotensin 2 Receptor Blocker
Increased Diuresis
Thiazide Diuretic
Thiazides

Price Statistics

The NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB has been published 536 times since Aug 17, 2016, and over the history we have for it it has declined 79.8%. The table below summarizes its recorded NADAC range and movement.

Current price$0.6313 per EA
All-time high$3.7501 (Jan 11, 2017)
All-time low$0.6313 (Nov 18, 2026)
52-week high$1.2226
52-week low$0.6313
Median price$1.7625
Average price$1.9806
Largest weekly change+48.6% (Aug 18, 2021)
Weeks tracked536
Tracking sinceAug 17, 2016

Price History

1W

-13.4%

1M

-23.0%

3M

-30.0%

6M

-46.6%

1Y

-42.7%

3Y

-61.5%

5Y

-63.2%

All

-79.8%

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?

The current National Average Drug Acquisition Cost (NADAC) for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB, manufactured by Macleods Pharmaceuticals Limited, is $0.6313 per EA (NDC 33342013210), effective Nov 18, 2026.

How has the price of CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB changed over time?

Over the history we have for it, the NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB has declined 79.8%. It has been tracked across 536 weekly CMS publications since Aug 17, 2016.

What are the highest and lowest recorded NADAC prices for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?

Since Aug 17, 2016, the NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB has ranged from a low of $0.6313 (Nov 18, 2026) to a high of $3.7501 (Jan 11, 2017), with a median of $1.7625 per EA.

Are there cheaper alternatives to CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?

2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB in a comparable dosage form, but none are currently priced below it.

Who manufactures CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?

CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB (NDC 33342013210) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.